Navigation Links
Marker of Ewing sarcoma: Potential new drug target?
Date:2/8/2010

Ewing sarcoma (EWS) is a bone tumor of unknown cellular origin that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown. Now, Katia Scotlandi and colleagues, at SSN Emilia Romagna Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy, have identified a crucial role for CD99 in the development of EWS and suggest that targeting CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS.

In the study, decreasing CD99 expression in human EWS cell lines reduced their ability to form tumors xenografted into mice. In vitro, it increased expression of H-neurofilament, a marker of neuronal differentiation. Consistent with this, an inverse correlation between CD99 expression and H-neurofilament expression, neural differentiation, and oncogenic transformation was observed in patient-derived EWS cells. The authors therefore conclude that CD99 prevents neural differentiation and suggest that blocking it might provide a new approach to treating EWS.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
2. Inflammation marker related to obesity is elevated in patients with pancreatic cancer
3. Biomarker could help doctors tailor treatment for rheumatoid arthritis
4. Genetic Marker for Aggressive Prostate Cancer Found
5. TGen analysis identifies biomarkers for diabetic kidney failure
6. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
7. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
8. Workshop tackles challenges in biomarker and drug development
9. Scientists identify specific markers that trigger aggressiveness of liver cancer
10. Biomedical Research Centre searches for immunological biomarkers
11. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/18/2017)... ... ... “Case #10-5411 Veterans Administration”: a personal account of corruption ... Administration” is the creation of published author, Carol Mulhern, single mother of two ... work at the Coatesville VAMC as a file clerk then later became the ...
(Date:8/17/2017)... ... August 17, 2017 , ... Shared leadership between ... extremely effective, very effective, or effective by 85% of respondents, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait left the ... took with her a dream to make nursing education more relevant and prepare aspiring ... skills were integrated into healthcare provider education. , “The human element was ...
(Date:8/17/2017)... ... August 17, 2017 , ... CARF ... three years for its residential drug and alcohol detox program. This accreditation decision ... and shows the organization’s substantial conformance to the CARF standards. , Behavioral health ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  AOTI Inc. announced today that its fully owned ... a New York City Office in Yonkers, New York ... Wound Oxygen (TWO 2 ) homecare therapy. This new East Coast ... Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment ... Advanced Oxygen Therapy ...
(Date:8/8/2017)... --   Second-quarter 2017 revenues ... per share from continuing operations ... percent to $110 million ... $161 million Second-quarter 2017 ... increased 8 percent to $0.93 ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
Breaking Medicine Technology: